Blackrock Neurotech
Develops brain-computer interface technology for medical research and clinical applications.
Company facts
- Founded
- 2008
- Employees
- 127
- Headquarters
- United States
- CEO
- Marcus Gerhardt
- Type
- Private
- Funding
- Corporate Round · $200M · 2024
About
At Blackrock Neurotech, we are dedicated to transforming lives through our advanced brain-computer interface (BCI) technologies. Founded in 2008, we have established ourselves at the forefront of neurotechnology innovation. Our mission is clear: we aim to restore independence to individuals suffering from paralysis and other neurological disorders by developing groundbreaking neurotechnologies. Our team comprises leading engineers and neuroscientists, all committed to this noble cause. Our flagship product, the MoveAgain Brain-Computer Interface, is designed for clinical use and represents a significant leap forward in assisting individuals to regain motor functions and improve their quality of life. This innovative device allows patients to perform daily activities—such as eating, typing, and even playing video games—simply by thinking about the movements. Our technology has been validated through numerous published studies, underscoring our commitment to scientific excellence and real-world impact. With a focus on blending neuroscience with engineering, we aspire to redefine what is possible for individuals living with disabilities.